CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
BPL-003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05674929
NCT05674929Phase 2Completed
CompareCT.gov

An Open-Label, Phase 2a Single Dose Study in Patients With Alcohol Use Disorder

Beckley Psytech Limited·interventional·Posted Jan 9, 2023·Updated May 22, 2026

In Brief

A Phase 2 clinical trial evaluating BPL-003 for Alcohol Use Disorder. Completed, enrolled 13 participants across 2 sites.

Detailed Summary

An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJan 9, 2023
Enrollment StartMay 30, 2023
Primary CompletionOct 2, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.5 years ago

Interventions

BPL-003drug

A single dose administered intranasally